At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 41 enrolled
Drug / intervention
Alisertib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Study of MLN8237, an Aurora A Kinase Inhibitor, in Patients With Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel Regimen
In Brief
A Phase 1 clinical trial evaluating Alisertib and Docetaxel for Advanced Solid Tumors and Adenocarcinoma of the Prostate. Completed, enrolled 41 participants across 4 sites.
Detailed Summary
The purpose of this study is to evaluate the safety and tolerability of alisertib in combination with docetaxel as a treatment for participants with advanced solid tumors, including castration-resistant prostate cancer, who were deemed by the investigator to be medically appropriate candidates for docetaxel therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 2010
Enrollment StartAug 2010
Primary CompletionFeb 2014
Study CompletionJan 2017
TodayJul 2026
First PostedMar 26, 2010
Enrollment StartAug 17, 2010
Primary CompletionFeb 28, 2014
Study CompletionJan 4, 2017
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 16.3 years ago
Interventions
Alisertibdrug
Alisertib ECT
Docetaxeldrug
Docetaxel IV infusion